Search Results - Birrell, Matt R.

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

    A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Ce... by Horwitz, Steven M., Feldman, Tatyana A., Hess, Brian T., Khodadoust, Michael S., Kim, Youn H., Munoz, Javier, Patel, Manish R., Phillips, Tycel J., Smith, Stephen D., Smith, Sonali M., Wilcox, Ryan A., Birrell, Matt R., Leeds, Janet M., Conley, Pamela B., Michelson, Glenn C., Coffey, Gregory P., Curnutte, John T., Hamlin, Paul A.

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab

    Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab by Smith, Stephen D., Munoz, Javier, Stevens, Don, Smith, Sonali M., Feldman, Tatyana A., Ye, J Christine, de Vos, Sven, Hess, Brian T., Miller, Carole B., Khatcheressian, James L., Birrell, Matt R., Leeds, Janet M., Coffey, Gregory P., Conley, Pamela B., Michelson, Glenn C., Curnutte, John T., Hamlin, Paul A.

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

    The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-... by Horwitz, Steven M., Feldman, Tatyana A., Hess, Brian T., Khodadoust, Michael S, Kim, Youn H., Munoz, Javier, Patel, Manish R, Phillips, Tycel J., Smith, Stephen D., Smith, Sonali M., Wilcox, Ryan A., Steele, Andrew, Pandey, Anjali, Birrell, Matt R, Leeds, Janet M., Conley, Pamela B., Michelson, Glenn, Coffey, Gregory P., Curnutte, John T, Hamlin, Paul A.

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B‐cell malignancies: Results of a phase I study

    Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B‐cell malignancies: Results of a phase I study by Hamlin, Paul A., Flinn, Ian W., Wagner‐Johnston, Nina, Burger, Jan A., Coffey, Greg P., Conley, Pamela B., Michelson, Glenn, Leeds, Janet M., Der, Kenneth, Kim, Yvonne, Sabalvaro‐Torres, Alice, Birrell, Matt, Pandey, Anjali, Curnutte, John T., Patel, Manish R.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    Clinical and Correlative Results of a Phase 1 Study of Cerdulatinib (PRT062070) a Dual SYK/JAK Inhibitor in Patients with Relapsed/Refractory B Cell Malignancies

    Clinical and Correlative Results of a Phase 1 Study of Cerdulatinib (PRT062070) a Dual SYK/JAK Inhibitor in Patients with Relapsed/Refractory B Cell Malignancies by Hamlin, Paul A, Flinn, Ian, wagner-Johnston, Nina, Burger, Jan A, Michelson, Glenn, Pandey, Anjali, Birrell, Matt, Coffey, Greg P., Leeds, Janet M, Curnutte, John T., Patel, Manish R.

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: